# Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

Source: https://onco.cc/trials/nct04195347/  
OnCo record `nct04195347` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by St. Jude Children's Research Hospital, now recruiting.

## Summary

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase is a phase 1/2, interventional study registered as NCT04195347 by St. Jude Children's Research Hospital, with a registry enrolment figure of 42 participants, started 2020-09-04 and due to reach its primary completion in 2027-01. Interventions recorded: CM4620. Conditions listed: Acute Pancreatitis. Primary outcome: The number of CTCAE grade 3-5 events; Responses to CM4620. Pancreatic eligibility wording from the registry: "* Acute pancreatitis with elevation of amylase OR lipase ≥ 3x the upper limit of normal AND at least 1 of: abdominal pain consistent with acute pancreatitis OR imaging findings consistent with acute pancreatitis". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT04195347
- Phase: 1/2
- Setting: CRSPA: Phase I/II Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
- Sponsor: St. Jude Children's Research Hospital
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT04195347: https://clinicaltrials.gov/study/NCT04195347

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04195347.json